NEOP | Neoprobe Corp Appoints Gordon A. Troup To BOD

Penny Stock News From The OTCBB

Jul 29, 2008 8:58:00 AM
Copyright Business Wire 2008

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, announced today that Gordon A. Troup has been appointed to Neoprobe Corporation's Board of Directors.

Mr. Troup recently retired as President of Cardinal Health's Nuclear Pharmacy Services (NPS). Mr. Troup spent 17 years with Cardinal Health, Inc. including five years as President of NPS and four years as Group President of Pharmaceutical Distribution and Specialty Distribution Services. At NPS Mr. Troup helped develop the largest radiopharmacy network in the United States with over 165 locations and 4000 employees. Mr. Troup has also been active in numerous professional and community organizations in the Columbus area and nationally.

Mr. Troup commented on his appointment to the Neoprobe Board of Directors, "I am excited to join the Board at Neoprobe because of the great potential the Company has in helping to improve the treatment and care of patients with cancer. Neoprobe has made great strides in the recent past and I look forward to assisting in guiding the company in the coming years as the company prepares for the commercial launch of Lymphoseek(R) and the development of additional products including its RIGS(R) technology."

David Bupp, Neoprobe's President & CEO, said, "Neoprobe is very pleased to have someone of Gordon's business experience and stature join our Board, as we are making the transition to a biotechnology company with both medical device and drug product offerings. Mr. Troup's business and marketing expertise will provide significant input as we prepare for the commercial launch of Lymphoseek and as we consider development strategies for our portfolio of biomedical products. Mr. Troup has been appointed to a Board term ending at the Annual Stockholders' Meeting in 2009, when he is expected to stand for election for another term ending in 2012."